Management of Crohn's disease.
作者信息
Rampton D S
机构信息
Gastrointestinal Science Research Unit, Digestive Diseases Research Centre, St Bartholomew's and the Royal London School of Medicine and Dentistry, London E1 2AD.
出版信息
BMJ. 1999 Dec 4;319(7223):1480-5. doi: 10.1136/bmj.319.7223.1480.
Abstract
摘要
相似文献
1
Management of Crohn's disease.
BMJ. 1999 Dec 4;319(7223):1480-5. doi: 10.1136/bmj.319.7223.1480.
2
Management of perianal Crohn's disease.
Clin Gastroenterol Hepatol. 2006 Apr;4(4):426-30. doi: 10.1016/j.cgh.2006.02.001.
3
Medical induction of active Crohn's ileitis: evidence-based management.
Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S247-8. doi: 10.1002/ibd.20711.
4
Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
Drugs. 2004;64(10):1069-89. doi: 10.2165/00003495-200464100-00004.
5
[Crohn's disease in monozygotic twins].
Nihon Shokakibyo Gakkai Zasshi. 1998 Feb;95(2):151-4.
6
Crohn's disease. Achieving optimum health status.
Adv Nurse Pract. 2004 May;12(5):28-35; quiz 35-6.
7
Medical management of Crohn's disease: a guide for radiologists.
Eur J Radiol. 2009 Mar;69(3):371-4. doi: 10.1016/j.ejrad.2008.11.028. Epub 2009 Feb 14.
8
Crohn disease: pathophysiology, diagnosis, and treatment.
Radiol Technol. 2014 Jan-Feb;85(3):297-316; quiz 317-20.
9
Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.
Am J Gastroenterol. 2015 Dec;110(12):1737-8. doi: 10.1038/ajg.2015.355.
10
Rosacea in Crohn's Disease: Effect of Rifaximin.
J Clin Gastroenterol. 2011 Mar;45(3):295-6. doi: 10.1097/MCG.0b013e3182040eb2.
引用本文的文献
1
New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer small molecule potentiators.
Medchemcomm. 2019 Mar 18;10(5):717-725. doi: 10.1039/c9md00010k. eCollection 2019 May 1.
2
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
Medchemcomm. 2018 Dec 20;10(1):169-179. doi: 10.1039/c8md00463c. eCollection 2019 Jan 1.
3
Stem Cell Applications for Treatment of Cancer and Autoimmune Diseases: Its Promises, Obstacles, and Future Perspectives.
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818806910. doi: 10.1177/1533033818806910.
4
Review of the use of intralesional steroid injections in the management of ileocolonic Crohn's strictures.
Frontline Gastroenterol. 2013 Oct;4(4):238-243. doi: 10.1136/flgastro-2012-100297. Epub 2013 Mar 27.
5
Ultrasound, CT and FDG PET-CT of a duodenal granuloma in a dog.
J Vet Med Sci. 2014 Jul;76(7):1073-7. doi: 10.1292/jvms.13-0627. Epub 2014 Apr 18.
6
Service evaluation of patients with orofacial granulomatosis and patients with oral Crohn's disease attending a paediatric oral medicine clinic.
Eur Arch Paediatr Dent. 2012 Aug;13(4):191-6. doi: 10.1007/BF03262869.
7
An update of the role of nutritional therapy in the management of Crohn's disease.
J Gastroenterol. 2012 Aug;47(8):872-82. doi: 10.1007/s00535-012-0617-9. Epub 2012 Jun 15.
8
Stem cells in clinical practice: applications and warnings.
J Exp Clin Cancer Res. 2011 Jan 17;30(1):9. doi: 10.1186/1756-9966-30-9.
9
Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study.
World J Gastroenterol. 2005 Dec 7;11(45):7118-21. doi: 10.3748/wjg.v11.i45.7118.
10
Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.
Cochrane Database Syst Rev. 2004;2003(1):CD003574. doi: 10.1002/14651858.CD003574.pub2.
本文引用的文献
1
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Gastroenterology. 1999 Oct;117(4):761-9. doi: 10.1016/s0016-5085(99)70332-x.
2
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
Gastroenterology. 1999 Sep;117(3):527-35. doi: 10.1016/s0016-5085(99)70445-2.
3
Infliximab for the treatment of fistulas in patients with Crohn's disease.
N Engl J Med. 1999 May 6;340(18):1398-405. doi: 10.1056/NEJM199905063401804.
4
Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease.
Gut. 1999 May;44(5):625-8. doi: 10.1136/gut.44.5.625.
5
Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group.
Gastroenterology. 1999 Feb;116(2):294-300. doi: 10.1016/s0016-5085(99)70125-3.
6
Visualising E-selectin in the detection and evaluation of inflammatory bowel disease.
Gut. 1998 Jul;43(1):40-7. doi: 10.1136/gut.43.1.40.
7
Place of laparoscopic surgery in Crohn's disease.
Baillieres Clin Gastroenterol. 1998 Mar;12(1):157-65. doi: 10.1016/s0950-3528(98)90090-2.
8
A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
N Engl J Med. 1998 Aug 6;339(6):370-4. doi: 10.1056/NEJM199808063390603.
9
Inflammatory bowel disease: etiology and pathogenesis.
Gastroenterology. 1998 Jul;115(1):182-205. doi: 10.1016/s0016-5085(98)70381-6.
10
Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study.
Gut. 1998 Apr;42(4):497-500. doi: 10.1136/gut.42.4.497.
Zotero 插件